Blueprint Medicines Corp (NASDAQ: BPMC) | The Mesh Report

Blueprint Medicines Corp (NASDAQ: BPMC)

Christian Tharp, CMT March 18, 2020 Comments Off on Blueprint Medicines Corp (NASDAQ: BPMC)

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. 

Take a look at the 1-year chart of Blueprint Medicines Corp (NASDAQ: BPMC) below with the added notations:

1-year chart of Blueprint Medicines Corp (NASDAQ: BPMC)

Over the course of the past two months, BPMC has formed an important level to watch at the $60 (blue) mark. That level was support in February, and now the stock has tested it as resistance multiple times in March.

The Tale of the Tape: BPMC has a key level at $60. A trader could enter a long position on a break above that level with a stop placed under it. However, if traders are bearish on the stock, a short trade could be made instead on a rally up to the $60 mark.

Before making any trading decision, decide which side of the trade you believe gives you the highest probability of success. Do you prefer the short side of the market, long side, or do you want to be in the market at all? If you haven’t thought about it, review the overall indices themselves. For example, take a look at the S&P 500. Is it trending higher or lower? Has it recently broken through a key resistance or support level? Making these decisions ahead of time will help you decide which side of the trade you believe gives you the best opportunities.

No matter what your strategy or when you decide to enter, always remember to use protective stops and you’ll be around for the next trade. Capital preservation is always key!

Good luck!
Christian Tharp, CMT

Comments are closed.